AbbVie Inc
For the period ended Dec 31, 2024. Filed Feb 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 14, 2025
ABBV$293.89+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Earnings
| years ended December 31 (in millions, except per share data) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net revenues | $56,334 | $54,318 | $58,054 |
| Cost of products sold | 16,904 | 20,415 | 17,414 |
| Selling, general and administrative | 14,752 | 12,872 | 15,260 |
| Research and development | 12,791 | 7,675 | 6,510 |
| Acquired IPR&D and milestones | 2,757 | 778 | 697 |
| Other operating expense (income), net | (7) | (179) | 56 |
| Total operating costs and expenses | 47,197 | 41,561 | 39,937 |
| Operating earnings | 9,137 | 12,757 | 18,117 |
| Interest expense, net | 2,160 | 1,684 | 2,044 |
| Net foreign exchange loss | 21 | 146 | 148 |
| Other expense, net | 3,240 | 4,677 | 2,448 |
| Earnings before income tax expense | 3,716 | 6,250 | 13,477 |
| Income tax expense (benefit) | (570) | 1,377 | 1,632 |
| Net earnings | 4,286 | 4,873 | 11,845 |
| Net earnings attributable to noncontrolling interest | 8 | 10 | 9 |
| Net earnings attributable to AbbVie Inc. | $4,278 | $4,863 | $11,836 |
| Per share data | |||
| Basic earnings per share attributable to AbbVie Inc. | $2.40 | $2.73 | $6.65 |
| Diluted earnings per share attributable to AbbVie Inc. | $2.39 | $2.72 | $6.63 |
| Weighted-average basic shares outstanding | 1,769 | 1,768 | 1,771 |
| Weighted-average diluted shares outstanding | 1,773 | 1,773 | 1,778 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.